Assunta Navarra

TL;DR: Commercial NAATs can be confidently used to exclude TB in patients with smear positive samples in which environmental mycobacteria infection is suspected and to confirm TB in a proportion of smear negative cases.

TL;DR: Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry and reduces COVID-19 mortality rate in a retrospective multicenter study and reduces intensive care unit admissions of CO VID-19 pneumonia.

TL;DR: The assay based on RD1 selected peptides has similar accuracy for active tuberculosis compared with TST and commercial IGRAs, however, the combined use of the novel assay or commercial I GRAs with T ST may allow exclusion of tuberculosis.

TL;DR: Findings may have important implications for the management of older adults with HIV, who should be targeted by appropriate public health actions, such as opportunistic screening and easier access to healthcare, and strategies including information on HIV and prevention of risk behaviours are needed.

TL;DR: The study of CD27 expression using different approaches, whether it involves evaluation of CD45RA expression or not, is a robust biomarker for discriminating TB stages.